Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors

Trial Profile

Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Vatreptacog alfa (Primary) ; Eptacog alfa
  • Indications Haemophilia
  • Focus Therapeutic Use
  • Acronyms adept2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Sep 2015 Results (post hoc analysis) published in the Journal of Thrombosis and Haemostasis.
    • 19 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top